Emily's Entourage » Press Releases

29 Sep 2022

Emily’s Entourage Gets Creative to Host 11th Annual Gala in a Post-Covid World

The event will celebrate 11 years of impact, including more than $10 million raised to speed breakthrough research for cystic fibrosis Co-Founder and family — in strict medically-related quarantine since March 2020 — to attend and broadcast annual speech live from secluded tent on-site Lower Merion, PA (Sept. 29, 2022) — How does a health-based nonprofit, led by a woman with advanced-stage lung...

19 Sep 2022

Patrick Harrison, PhD, Joins Emily’s Entourage Scientific Advisory Board

As Head of the Gene Editing Lab at University College Cork, Ireland, Dr. Harrison led the group that reported the first successful correction of a CFTR mutation in a cell model of cystic fibrosis Lower Merion, PA — Sept. 19, 2022 — Emily’s Entourage (EE), an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for the final 10%...

12 Sep 2022

Emily’s Entourage Announces Addition of David M. Bedwell, PhD, to its Scientific Advisory Board

Dr. Bedwell joins seven other highly respected and experienced researchers, clinicians, and health industry leaders to provide guidance on strategic research priorities for the organization Lower Merion, PA — Sept. 12, 2022 — Emily’s Entourage (EE), an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for the final 10% of people with cystic fibrosis (CF), including those with...

10 Feb 2022

Emily’s Entourage Announces Chandrabali Ghose, PhD, as First-Ever Chief Scientific Officer

Dr. Chandra Ghose will lead the organization’s research and development activities to speed therapeutic developments for individuals with rare forms of cystic fibrosis (CF) Lower Merion, PA – Emily’s Entourage (EE), an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of cystic fibrosis (CF), announces the appointment of Dr. Chandra Ghose as the organization’s first-ever...

23 Nov 2021

Emily’s Entourage Hosts 10th Annual Evening With Emily’s Entourage Drive-in Gala, “The Power of 10,” Celebrating 10 Years of Impact and Nearly $10 Million Raised

Pennsylvania-based nonprofit has funded 22 research grants and secured $37.6+ million in follow-on funding to speed breakthroughs for people with nonsense mutations of cystic fibrosis Lower Merion, PA — Emily’s Entourage, an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of cystic fibrosis (CF), will host its 10th annual Evening with Emily’s Entourage drive-in gala,...

14 May 2021

EE Presents “The Magic Line: Drawing A Future Without Cystic Fibrosis”

A Virtual Event, Emily Entourage’s 6th Annual EENY Program Raises Critical Funds for Cystic Fibrosis Research New York, NY — Emily’s Entourage (EE), an innovative 501(c)3 foundation that has raised millions of dollars since 2011 to speed research and drug development for Cystic Fibrosis (CF), is proud to announce a virtual event, “The Magic Line: Drawing A Future Without Cystic Fibrosis” on...

05 Nov 2019

Nonprofit Emily’s Entourage is Encouraged to See CF Gene Therapy Advance Through Spirovant Acquisition

Acquisition will advance two mutation-agnostic gene therapy programs for Cystic Fibrosis, a rare disease that affects 70,000 people worldwide. Lower Merion, PA — Emily’s Entourage, an innovative 501(c)3 foundation that has raised millions of dollars since 2011 to speed groundbreaking treatments and a cure for rare nonsense mutations of Cystic Fibrosis, welcomes with great enthusiasm the news that Sumitomo Dainippon Pharma, in...

21 Oct 2019

Statement from Emily’s Entourage regarding FDA approval of breakthrough therapy for Cystic Fibrosis

Today is a monumental day in the history of Cystic Fibrosis (CF) treatments and the history of medicine. The FDA announced its approval of the highly-anticipated triple combination therapy, Trikafta, developed by Vertex Pharmaceuticals, for 90% of the CF population ages 12 and older who have at least one copy of the most common CF mutation, F508del. Trifakta does not benefit those...